Clinical trials: Vaginal Delivery
Luteal Hormone Supplementation in In-vitro Fertilization, Embryo Transfer
Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel
The primary objective of this trial is to demonstrate the non-inferiority of the clinical pregnancy rate per embryo transfer to the historical standard value in in-vitro fertilization (IVF)/embryo transfer (ET) cycles in Japan…
- Trial name
- NCT01863680
- Testing
- COL-1620, Gonadotropin-releasing hormone (GnRH) analogue, Follicle-stimulating hormone (FSH)
- Where
- 5 sites in Japan
- Volunteers
- 178 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Vaginal Laxity Following Childbirth, Sexual Function Following Childbirth
VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness
Outside United States (OUS) Post-Market Parallel Group Exploratory Study Design The objective of this study is to determine the safety and effectiveness of the Viveve System to treat the vaginal introitus in women following…
- Trial name
- VIVEVE I (NCT02261974)
- Testing
- Active Treatment Viveve
- Where
- 9 sites in Canada, Italy and 2 more
- Volunteers
- 186 people
- Sponsor
- Viveve Inc.
Luteal Hormone Supplementation
A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment
The purposes of the study are to verify sufficient supplementation of luteal hormone after administrating FE999913 Vaginal Tablet twice a day (BID) or three times a day (TID) and to determine the efficacy and safety of FE999913…
- Trial name
- NCT01710514
- Testing
- FE 999913 vaginal tablet
- Where
- 6 sites in Japan
- Volunteers
- 108 people
- Sponsor
- Ferring Pharmaceuticals
Reducing Time to Vaginal Delivery, Cervical Ripening
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant…
- Conditions
- Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
- Trial name
- EXPEDITE (NCT01127581)
- Testing
- MVI 200, Dinoprostone Vaginal Insert (DVI)
- Where
- 34 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Ferring Pharmaceuticals
Preterm Delivery, Short Cervix
PREGNANT Short Cervix Trial
The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel in decreasing the preterm birth rate in a population of pregnant women with short cervical length and at high risk for preterm birth.
- Conditions
- Preterm Delivery, Short Cervix, Short Uterine Cervical Length
- Trial name
- NCT00615550
- Testing
- progesterone
- Where
- 49 sites in United States, Belarus and 8 more
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Post-Partum Hemorrhage
Fibrinogen in Haemorrhage of Delivery
The purpose of the study is to assess the benefits of a therapeutic strategy that associates an early administration of human fibrinogen concentrate in the management of PPH on the reduction of bleeding after the initiation of…
- Trial name
- FIDEL (NCT02155725)
- Testing
- Human Fibrinogen concentrate
- Where
- 31 sites in France, Martinique
- Volunteers
- 448 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies